General meetings
The shareholders’ right to decide on the company’s affairs is exercised at its highest decision-making body – the general meeting (the annual general meeting or an extraordinary general meeting).
General Meetings
The general meeting decides, for example, on changes to the articles of association, the election of the Board of Directors and auditors, adoption of the income statement and balance sheet, discharge from liability of the Board of Directors and the CEO, the appropriation of profit or loss, the principles for the appointment of the nomination committee and remuneration guidelines for the Management Team.
General meetings shall be held in Lund, Sweden. Notice convening the annual general meetings and extraordinary general meetings where amendments to the articles of association are to be addressed, shall be issued no earlier than six weeks and no later than four weeks prior to the meeting. Notice convening other extraordinary general meetings shall be issued no earlier than six weeks and no later than three weeks prior to the meeting. A shareholder who wishes to have a matter considered by the Annual General Meeting on may submit a written request to the Board. Proposals for the agenda shall be submitted no later than seven weeks before the Annual General Meeting.
Immunovia Annual General Meeting, 13 May 2026
- Notice of Annual General Meeting 2026
- The Nomination Committee’s proposal and reasoned statement
- Resolution on (A) an option programme for senior executives and key personnel; and (B) a directed issue of warrants and approval of transfer of warrants
- Resolution on (A) an option programme for Board members; and (B) a directed issue of warrants and approval of transfer of warrants
- Proposal for authorisation for the Board to resolve on a new share issue
- Proxy form
- The auditor’s statement
- Annual report
- Remuneration report
- Immunovia AB – Minutes of the Annual General Meeting 2026
Immunovia Extraordinary General Meeting, 29 September 2025
Immunovia Annual General Meeting, 14 May 2025
- Notice of Annual General Meeting 2025
- The Nomination Committee’s proposal and reasoned statement
- Resolution on (A) an option programme for senior executives and key personnel; and (B) a directed issue of warrants and approval of transfer of warrants
- Resolution on (A) an option programme for Board members; and (B) a directed issue of warrants and approval of transfer of warrants
- Proposal for authorisation for the Board to resolve on a new issue of shares
Immunovia Annual General Meeting, 19 June 2024
- Notice of Annual General Meeting 2024
- Statement from the Nomination Committee 2024
- Remuneration report
- Proposed guidelines for remuneration
- Proposed resolution to reduce the share capital
- Proposed resolution to amend the Articles of Association
- Proposed resolution on authorisation for the Board to issue shares and warrants to guarantors
- Proposed resolution on authorisation for the Board to resolve on a new issue of shares
- Annual report 2023
- Proxy form
- Auditor’s statement
- Auditor’s statement – Senior executives
- Minutes of the Annual General Meeting on 19 June 2024
Immunovia Extraordinary General Meeting, 21 November 2023
Immunovia Extraordinary General Meeting, 16 March 2023
Immunovia Annual General Meeting, 7 April 2022
Immunovia Extraordinary General Meeting, 23 September 2020
Immunovia Annual General Meeting, 26 April 2019
Immunovia Annual General Meeting, 3 May 2018
- Notice of Immunovia’s Annual General Meeting 2018 (PDF in Swedish)
- Report from the Annual General Meeting (PDF in English)
- Immunovia AGM communiqué (PDF in Swedish)
- Minutes of the Annual General Meeting 2018 (PDF in Swedish)
- Item 9: The Nomination Committee’s proposal
- Item 10: Guidelines for remuneration to senior executives
- Item 11: Principles for the Nomination Committee
- Item 12: Authorisation for the Board to resolve on a new share issue
- Item 13: Issue of warrants for key personnel etc.
- Item 14: Amendment of the Articles of Association